CasLoc logo
All Cases PTAB Litigations UPC Oppositions

AbbVie Inc. v. Aurobindo Pharma Limited

1:17-cv-00047

Overview

Case Number 1:17-cv-00047
Filing Date 2017-01-13
Status Terminated
Termination Date 2017-02-24
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Aurobindo Pharma Limited NPE (University / Research)

Represented By

1 Attorneys Listed

Arthur G. Connolly , III

Connolly Gallagher LLP

Tel: +1 (302) 757-7300

1201 North Market Street, 20th Floor, Wilmington, DE 19801

Aurobindo Pharma USA, Inc. Operating Company

Represented By

1 Attorneys Listed

Arthur G. Connolly , III

Connolly Gallagher LLP

Tel: +1 (302) 757-7300

1201 North Market Street, 20th Floor, Wilmington, DE 19801

AbbVie Inc. Operating Company

Represented By

2 Attorneys Listed

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Mary B. Graham

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Plaintiff

Abbvie Deutschland GMBH & Co. KG Operating Company

Represented By

2 Attorneys Listed

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Mary B. Graham

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 9 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (9 found):
U.S. Courts: 9
U.S. District Court 2016-05-27
1:16-cv-00398

AbbVie Inc. v. Amneal Pharmaceuticals, LLC

Asserted Patent
Status: DED
U.S. District Court 2015-10-02
1:15-cv-00889

AbbVie Inc. v. Hetero USA Inc.

Asserted Patent
Status: DED
U.S. District Court 2014-09-25
1:14-cv-01236

AbbVie Inc. v. Mylan Pharmaceuticals Inc.

U.S. Family Sibling (["US8691878"])
Status: DED
U.S. District Court 2014-09-05
1:14-cv-01137

AbbVie Inc. v. Hetero Labs Limited

U.S. Family Sibling (["US8691878"])
Status: DED
U.S. District Court 2014-07-18
1:14-cv-00959

AbbVie Inc. v. Aurobindo Pharma Limited

Asserted Patent
Status: DED
U.S. District Court 2013-07-03
2:13-cv-00645

AbbVie Inc. v. Roxane Laboratories Inc.

Asserted Patent
Status: OHSD
U.S. District Court 2013-06-14
1:13-cv-01072

AbbVie Inc. v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-05-15
1:13-cv-00852

AbbVie Inc. v. Hetero USA Inc.

Asserted Patent
Status: DED
U.S. District Court 2012-04-10
1:12-cv-00457

AbbVie Inc. v. Roxane Laboratories Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

9 Patents

There are 9 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7148359
Polymorph of a pharmaceutical
Filed: 2005-05-04
Issued: 2006-12-12
Expired (Term Ended)
Expires: 2025-05-04
US7364752
Solid dispersion pharamaceutical formulations
Filed: 2000-11-10
Issued: 2008-04-29
Expired (Term Ended) +688d PTA
Expires: 2022-09-29
US8025899
Solid pharmaceutical dosage form
Filed: 2004-08-25
Issued: 2011-09-27
Active (1.1 yrs remaining) +1206d PTA
Expires: 2027-12-14
US8268349
Solid pharmaceutical dosage form
Filed: 2012-04-18
Issued: 2012-09-18
Active (5.4 yrs remaining)
Expires: 2032-04-18
US8309613
Solid pharmaceutical dosage form
Filed: 2010-09-13
Issued: 2012-11-13
Expired (Term Ended)
Expires: 2024-12-24

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(9 total)
Pleading / Complaint

COMPLAINT filed against Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2064987.) - filed by Abbvie Deutschland GMBH & Co. KG, AbbVie Inc.. (Attachments: # 1 Exhibit A-I, # 2 Civil Cover Sheet)(jcs) (Entered: 01/17/2017)

Entry #1 • 2017-01-13
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jcs) (Entered: 01/17/2017)

Entry #2 • 2017-01-13
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: December 1, 2016. Date of Expiration of Patent: See attached.Thirty Month Stay Deadline: 6/1/2019. (jcs) (Entered: 01/17/2017)

Entry #3 • 2017-01-13
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) - See attached. (jcs) (Entered: 01/17/2017)

Entry #4 • 2017-01-13
1

No Summons Issued

Entry #5 • 2017-01-17
1
No Actions

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc